Prednison acis 5 mg
Sponsors
Janssen - Cilag International, AbbVie Deutschland GmbH & Co. KG, Janssen Cilag International, Jiangsu Hengrui Pharmaceuticals Co. Ltd., Exelixis Inc.
Conditions
Chronic Graft Versus Host Disease (cGVHD)Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)Geographic AtrophyMetastatic Castration-Resistant Prostate CancerMetastatic Castration-resistant Prostate Cancer (mCRPC)Metastatic Prostate CancerMetastatic castration-resistant prostate cancer (mCRPC)PSMA-positive mCRPC with prior exposure to at least one prior ARPI
Phase 1
Phase 1/2 Dose Finding, Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)
CompletedCTIS2023-507330-24-00
Start: 2019-02-07End: 2025-01-20Target: 14Updated: 2024-12-17
A phase Ib/II open-label, multi-center study of the DNA protein kinase inhibitor AMO959 with lutetium (177Lu) vipivotide tetraxetan (AAA617) in combination with an androgen receptor pathway inhibitor (ARPI) in adult participants with PSMA-positive metastatic castration resistant prostate cancer (mCRPC)
Not yet recruitingCTIS2025-521859-23-00
Target: 61Updated: 2026-03-06
Phase 2
A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Active, not recruitingCTIS2022-500746-16-00
Start: 2023-08-11Target: 118Updated: 2025-12-15
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies
RecruitingCTIS2022-500747-21-00
Start: 2025-02-27Target: 120Updated: 2025-08-25
Phase 3
A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)
Active, not recruitingCTIS2023-508606-26-00
Start: 2015-04-23Target: 5Updated: 2025-06-27
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined with Abiraterone Acetate and Prednisone (AA-P) versus Placebo Combined with AA-P as First-Line Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer
Active, not recruitingCTIS2023-509396-16-00
Start: 2021-11-08Target: 136Updated: 2025-12-05
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Active, not recruitingCTIS2023-506365-64-00
Start: 2020-10-16Target: 211Updated: 2026-01-13
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer
Active, not recruitingCTIS2023-503254-12-00
Start: 2019-03-06Target: 235Updated: 2025-12-09
A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer
Active, not recruitingCTIS2024-516481-11-00
Start: 2020-09-22Target: 203Updated: 2025-12-04
A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer
Not yet recruitingCTIS2025-522713-29-00
Target: 63Updated: 2026-03-10